About Airmeith Bioscience
ABout us
Airmeith Bioscience evolved from Transgenics TCD to explore new corners of in vivo preclinical research.
In 2026, we founded Airmeith Bioscience — a new chapter built on over a decade of experience in genetic technologies and preclinical research — to advance therapeutic innovation in Ireland and beyond. Airmeith was created to serve this new era of drug discovery, encompassing small molecules, biologics, and living therapies.
The landscape of therapeutic development is changing faster than ever. Advances in genomics, gene editing, regenerative medicine, and artificial intelligence are reshaping how we understand and treat disease. The boundaries between discovery, model development, and clinical application are dissolving — demanding integrated, translational approaches grounded in robust biological insight.
At Airmeith Bioscience, we believe that the future of medicine lies in the seamless connection between innovation and validation — between the lab bench and the patient bedside. Our expertise in complex genetic models and preclinical research ensures that the next generation of therapies is not only groundbreaking, but also safe, ethical, and effective. We are committed to driving forward a future where science moves faster, smarter, and more responsibly toward transformative treatments that improve human health.
MEET THE TEAM
Claire Fergus
Co-founder & CEO
Vincent Kelly
Co-founder & CSO
Ciara Nulty
Operations Director
Our facilities
Our state-of-the-art facility itself has specific opportunistic pathogen free (SOPF) status, with a vast rage of specialist equipment and IVCs with intra-cage humidity control, and HEPA-filtered cabinets for housing of immunocompromised models, surgical suites with incubators, microinjectors, stereomicroscopes and class II cabinets and CASA (Computer Assisted Sperm Analysis) image analysis systems. Access to tissue culture laboratories (up to Cat III), fully equipped histochemistry, confocal microscopy and flow cytometry suites allow for comprehensive downstream analysis in your end-to-end project. The facility is continually evolving in the technologies we provide, and we welcome your suggestions on how we can accelerate your research efforts.
Our History
Originally established in 2011 as the Transgenics TCD Facility at Trinity College dublin by Professor Vincent Kelly, our mission was to serve as enabling resource for the higher education sector.
As our understanding of the DNA code and its role in human health, disease, and therapeutics depend, it became clear that genetically altered models of disease were essential to translate basic research discoveries into real-world treatments. The Transgenics TCD Facility was the exclusive centre in Ireland for the design and generation of new genetic models, offering expert advice and services around complex transgenic and knockout models.
Over the intervening years, the facility expanded its offerings in preclinical research and has successfully delivered hundreds of projects for clients in both academia and industry. Our deep expertise in complex genetic models has supported large consortium projects requiring advanced in vivo capability, technical precision, and ethical study design. Our reputation for rigorous, complaint, and high-quality research has fostered storing industrial collaborations and partnerships across sectors.
Interested in joining our team?
If you’re ready to help shape a smarter, more connected future for therapeutic discovery, we’d love to meet you